| Aherrahrou Zouhair |
Targeting the Hypothalamic Complement System: A Novel Approach to Combatting Obesity
|
| Ajò Alessandro |
Use of the RNA Technology for the therapy of infectious diseases based on humoral innate immunity molecules
|
| Albornoz Eduardo |
The Role of Complement Receptor C5aR1 in a Murine Glioblastoma Model
Therapeutic inhibition of complement C5aR1 is neuroprotective in Parkinson’s disease preclincal models
|
| Alkhateeb Haya |
Inhibition of the C1s Protease and the Classical Complement Pathway by
6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide and Chemical Analogs
|
| Alo Bekas |
Towards cyclic peptides targeting the complement system
|
| Andersen Gregers |
Cryo-EM analysis of complement C3 reveals a reversible major opening of the macroglobulin ring
Structure-function analysis of ARGX-117, a calcium- and pH-dependent clinical phase complement C2 blocking antibody
|
| Andrade Gabriela |
Dynamic changes in Cytokines and Complement biomarkers during COVID-19: Implications for disease severity and outcomes.
|
| Angelidou1 Artemis |
Intracellular C1r promotes kidney cancer progression
|
| Antoniadou Christina |
C3 targeting with AMY-101 diminishes IL-8-driven neutrophil chemotaxis in severe COVID-19
|
| Aponte Rafael |
Obesity and metabolic health shapes mucosal complement responses
|
| Arepally Gowthami |
Inhibition of the C1s Protease and the Classical Complement Pathway by
6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide and Chemical Analogs
|
| Armento Angela |
Understanding the effects of ARMS2 and its AMD risk variant A69S on extracellular matrix and complement system
Analysing and targeting complement activity in age related macula degeneration of the eye
Intracellular complement FH promotes renal cancer by modulation of the cell cycle and energy metabolism in fibroblasts and tumour cells
Investigating the impact of complement sources and Complement Factor H (CFH) Y402H polymorphism on the stress response of iPSC-RPE cells
|
| Artero Mikel |
In situ Complementomics reveals pathological intracellular action of complement C3 in diseases affecting the kidney
|
| Barbai Veronika |
The complex complement modulatory role of the human factor H-related proteins
|
| Baz Morelli Adriana |
Complement pathway inhibition by LHR domain-based duplication variants of Complement Receptor 1.
|
| Bechtler Clément |
The crystal structure of the Factor H-recruiting peptide 5C6 in complex with Factor H domains 8-14 demonstrates an unprecedented domain arrangement in Factor H and allows for rational optimisation of the 5C6 peptide
|
| Beining Max |
Towards cyclic peptides targeting the complement system
|
| Bencze Dániel |
The complex complement modulatory role of the human factor H-related proteins
|
| Berthenet Kevin |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Binder Christoph J. |
Complement control in chronic inflammation and atherosclerosis
|
| Bishop Paul |
Nonclinical evaluation of CTx001, a gene therapy for the treatment of geographic atrophy in aged-related macular degeneration
|
| Blom Anna |
Protective functions of cytosolic C3 in pancreatic beta cells.
|
| Borsa Nicolo |
Immune complex glomerulonephritis and C3 glomerulopathy in 2024 – state of the art
|
| Bosmann Markus |
Concomitant deficiency of C5aR1 and C5aR2 drives neutrophil dysregulation resulting in increased susceptibility to pneumococcal infection
|
| Bottazzi Barbara |
Roles of PTX3 in clearance of SARS-CoV-2 via macrophage phagocytosis of infected epithelial cells
Development of mannose binding lectin as therapeutic agent in COVID-19
|
| Boudhabhay Idris |
Intracellular C1r promotes kidney cancer progression
Intracellular complement FH promotes renal cancer by modulation of the cell cycle and energy metabolism in fibroblasts and tumour cells
In situ Complementomics reveals pathological intracellular action of complement C3 in diseases affecting the kidney
|
| Bovin Lone |
Comprehensive Immunogenicity Analysis of AAV Therapies: Correlating Anti-AAV Antibodies (NAbs/TAbs) with Complement Activation Dynamics
|
| Boyle Aimee |
selection and characterization of a peptide-based complement activator
|
| Bracke Laura |
Structure-function analysis of ARGX-117, a calcium- and pH-dependent clinical phase complement C2 blocking antibody
The story of empasiprubart (ARGX-117), an inhibitory C2 antibody with sweeping properties, from healthy volunteers to three phase 2 proof-of-concept studies
|
| Bradyanova Silviya |
C1q-mimiking scFv fragments binding anti-C1q autoantibodies modulate disease progression in MRL/lpr mouse model of Systemic Lupus Erythematosus
|
| Brekke Ole |
Combined complement C3 and CD14 inhibition efficiently reduce the E. coli-induced thromboinflammation in human whole blood in the absence and presence of antibiotics
|
| Brenner Michael |
Granzyme K activates a new complement pathway
|
| Brouwer Mieke |
Anti-FHR-1 antibodies reacting against domain 18 of complement factor H have opposing effects on its function; implications for therapeutic enhancement of FH
|
| Bubeck Doryen |
Regulating the complement membrane attack complex
|
| Butler Samuel |
Elucidating Complement Activation Mechanisms in AAV Gene Therapy: Development of a Novel ELISA-Based Assay for Enhanced Safety and Efficacy
Comprehensive Immunogenicity Analysis of AAV Therapies: Correlating Anti-AAV Antibodies (NAbs/TAbs) with Complement Activation Dynamics
|
| Campbell Joshua |
Concomitant deficiency of C5aR1 and C5aR2 drives neutrophil dysregulation resulting in increased susceptibility to pneumococcal infection
|
| Carriero Roberta |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Celik Selvi |
Comprehensive Immunogenicity Analysis of AAV Therapies: Correlating Anti-AAV Antibodies (NAbs/TAbs) with Complement Activation Dynamics
|
| Chaudhuri Suhnrita |
Nonclinical evaluation of CTx001, a gene therapy for the treatment of geographic atrophy in aged-related macular degeneration
|
| Chavakis Triantafyllos |
Bone-marrow mediated trained immunity
|
| Cianchi Virginia |
Development of mannose binding lectin as therapeutic agent in COVID-19
Use of the RNA Technology for the therapy of infectious diseases based on humoral innate immunity molecules
|
| Ciullo Lorella |
Towards cyclic peptides targeting the complement system
|
| Clark Simon J. |
Analysing and targeting complement activity in age related macula degeneration of the eye
Investigating the impact of complement sources and Complement Factor H (CFH) Y402H polymorphism on the stress response of iPSC-RPE cells
Nonclinical evaluation of CTx001, a gene therapy for the treatment of geographic atrophy in aged-related macular degeneration
|
| Colineau Lucie |
Protective functions of cytosolic C3 in pancreatic beta cells.
|
| Connolly E. Sander |
Complement Activity in Emboli Retrieved During Thrombectomy for Ischemic Stroke
|
| Connolly Jr. E. Sander |
Complement Activity in Emboli Retrieved During Thrombectomy for Ischemic Stroke
|
| Criss Alison |
Complement C5b-C8 and C5b-C9 membrane attack complexes differentially potentiate antimicrobial activity against drug-resistant Neisseria gonorrhoeae
|
| Cserhalmi Marcell |
The complex complement modulatory role of the human factor H-related proteins
|
| Csincsi Ádám |
The complex complement modulatory role of the human factor H-related proteins
|
| Daha1 Mohamed R. |
The association of the complotype with on long-term outcome in kidney transplantation
|
| Dambra Monica |
The role of complement in pancreatic cancer: from complement activation triggering and effector mechanism/s to combination with classical therapies
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| De Cola Luisa |
Use of the RNA Technology for the therapy of infectious diseases based on humoral innate immunity molecules
|
| de Deus Marina |
Dynamic changes in Cytokines and Complement biomarkers during COVID-19: Implications for disease severity and outcomes.
|
| de la Cerda Berta |
Investigating the impact of complement sources and Complement Factor H (CFH) Y402H polymorphism on the stress response of iPSC-RPE cells
|
| De Winter Karen |
The story of empasiprubart (ARGX-117), an inhibitory C2 antibody with sweeping properties, from healthy volunteers to three phase 2 proof-of-concept studies
|
| Dekkers Gillian |
Anti-FHR-1 antibodies reacting against domain 18 of complement factor H have opposing effects on its function; implications for therapeutic enhancement of FH
|
| Delaere Jolien |
The story of empasiprubart (ARGX-117), an inhibitory C2 antibody with sweeping properties, from healthy volunteers to three phase 2 proof-of-concept studies
|
| Delahaye Tim |
Structure-function analysis of ARGX-117, a calcium- and pH-dependent clinical phase complement C2 blocking antibody
The story of empasiprubart (ARGX-117), an inhibitory C2 antibody with sweeping properties, from healthy volunteers to three phase 2 proof-of-concept studies
|
| Desai Jigar |
The Roles of Complement C3 and C5 in Pulmonary Antifungal Immunity
|
| Deschatelets Pascal |
Complement signaling as an immune checkpoint in the ovarian cancer microenvironment
|
| Dettner Alina |
Does C2b have a role in inflammation?
|
| Dias Erika |
Dynamic changes in Cytokines and Complement biomarkers during COVID-19: Implications for disease severity and outcomes.
|
| Didangelos Athanasios |
Nonclinical evaluation of CTx001, a gene therapy for the treatment of geographic atrophy in aged-related macular degeneration
|
| Dimitrov Jordan |
Intracellular complement FH promotes renal cancer by modulation of the cell cycle and energy metabolism in fibroblasts and tumour cells
|
| Donado Carlos |
Granzyme K activates a new complement pathway
|
| Dopler Arthur |
The crystal structure of the Factor H-recruiting peptide 5C6 in complex with Factor H domains 8-14 demonstrates an unprecedented domain arrangement in Factor H and allows for rational optimisation of the 5C6 peptide
|
| Doychinova Irini |
Selective suppression of pathogenic B lymphocytes from Hashimoto's thyroiditis patients by chimeric protein molecules
|
| Duan Huiquan |
Inhibition of the C1s Protease and the Classical Complement Pathway by
6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide and Chemical Analogs
|
| Dudek Markus |
Concomitant deficiency of C5aR1 and C5aR2 drives neutrophil dysregulation resulting in increased susceptibility to pneumococcal infection
|
| Eitel Ingo |
Targeting the Hypothalamic Complement System: A Novel Approach to Combatting Obesity
|
| Emblem Åse |
Combined complement C3 and CD14 inhibition efficiently reduce the E. coli-induced thromboinflammation in human whole blood in the absence and presence of antibiotics
|
| Emery-Billcliff Peter |
Nonclinical evaluation of CTx001, a gene therapy for the treatment of geographic atrophy in aged-related macular degeneration
|
| Ewert Svenja |
Complement pathway inhibition by LHR domain-based duplication variants of Complement Receptor 1.
|
| Farouqa Jad |
The Role of Complement Receptor C5aR1 in a Murine Glioblastoma Model
|
| Felsch Jannes |
The crystal structure of the Factor H-recruiting peptide 5C6 in complex with Factor H domains 8-14 demonstrates an unprecedented domain arrangement in Factor H and allows for rational optimisation of the 5C6 peptide
|
| Fernandez-Godino Rosario |
Investigating the impact of complement sources and Complement Factor H (CFH) Y402H polymorphism on the stress response of iPSC-RPE cells
|
| Ferrando-Miguel Rosa |
Titration of the biological activities Anaphylatoxins using reporter cell lines
|
| Foco Luisa |
Genome-wide association screening of complement activation – data from a general population study
|
| Gaboriaud Christine |
Intracellular C1r promotes kidney cancer progression
|
| Gadeberg Trine |
Cryo-EM analysis of complement C3 reveals a reversible major opening of the macroglobulin ring
|
| Gadotti Ana Carolina |
Dynamic changes in Cytokines and Complement biomarkers during COVID-19: Implications for disease severity and outcomes.
|
| Garcia Brandon |
Inhibition of the C1s Protease and the Classical Complement Pathway by
6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide and Chemical Analogs
Insights into the molecular basis for inhibition of the classical pathway by C1 esterase inhibitor
|
| Garlanda Cecilia |
Development of mannose binding lectin as therapeutic agent in COVID-19
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
Use of the RNA Technology for the therapy of infectious diseases based on humoral innate immunity molecules
Roles of PTX3 in clearance of SARS-CoV-2 via macrophage phagocytosis of infected epithelial cells
The role of complement in pancreatic cancer: from complement activation triggering and effector mechanism/s to combination with classical therapies
|
| Garrigues Ryan |
Insights into the molecular basis for inhibition of the classical pathway by C1 esterase inhibitor
|
| Garrison Matthew |
Insights into the molecular basis for inhibition of the classical pathway by C1 esterase inhibitor
|
| Gavriilidis Efstratios |
C3 targeting with AMY-101 diminishes IL-8-driven neutrophil chemotaxis in severe COVID-19
|
| Geisbrecht Brian |
Inhibition of the C1s Protease and the Classical Complement Pathway by
6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide and Chemical Analogs
|
| Germanidis Georgios |
C3 targeting with AMY-101 diminishes IL-8-driven neutrophil chemotaxis in severe COVID-19
|
| Ghebrehiwet Berhane |
The role of C1q and gC1qR as a novel checkpoint in cancer
|
| Giridharan Thejaswini |
Complement signaling as an immune checkpoint in the ovarian cancer microenvironment
|
| Gobbo Emilie |
Titration of the biological activities Anaphylatoxins using reporter cell lines
|
| Gragoll Carolin |
Targeting the Hypothalamic Complement System: A Novel Approach to Combatting Obesity
|
| Green Rachel |
Nonclinical evaluation of CTx001, a gene therapy for the treatment of geographic atrophy in aged-related macular degeneration
|
| Grioni Andrea |
Further insights into iptacopan mode of action in IgA nephropathy through protein profiling
|
| Grizzi Fabio |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Grønli Renathe |
Combined complement C3 and CD14 inhibition efficiently reduce the E. coli-induced thromboinflammation in human whole blood in the absence and presence of antibiotics
|
| Guido Poli |
Roles of PTX3 in clearance of SARS-CoV-2 via macrophage phagocytosis of infected epithelial cells
|
| Gytz Heidi |
BiCE™ – An antibody platform to potentiate complement activation for the treatment of cancer and autoimmune diseases.
|
| Hack Erik |
Structure-function analysis of ARGX-117, a calcium- and pH-dependent clinical phase complement C2 blocking antibody
|
| Hajishengallis George |
Maladaptive trained immunity and chronic inflammation
|
| Halbgebauer Rebecca |
Is there a bright side of complement after trauma?
|
| Hamers Sebastiaan |
selection and characterization of a peptide-based complement activator
|
| Hammad Hani |
The complex complement modulatory role of the human factor H-related proteins
|
| Hardy Matthew |
Complement pathway inhibition by LHR domain-based duplication variants of Complement Receptor 1.
|
| Harris Dalia |
Obesity and metabolic health shapes mucosal complement responses
|
| Haspeslagh Eline |
The story of empasiprubart (ARGX-117), an inhibitory C2 antibody with sweeping properties, from healthy volunteers to three phase 2 proof-of-concept studies
|
| Herdendorf Timothy |
Inhibition of the C1s Protease and the Classical Complement Pathway by
6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide and Chemical Analogs
|
| Holers Michael |
The association of the complotype with on long-term outcome in kidney transplantation
|
| Huber-Lang Markus |
C3 targeting with AMY-101 diminishes IL-8-driven neutrophil chemotaxis in severe COVID-19
Does C2b have a role in inflammation?
Is there a bright side of complement after trauma?
|
| Ikkert Oksana |
Further insights into iptacopan mode of action in IgA nephropathy through protein profiling
|
| Jaillon Sebastien |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Jarboui Mohamed |
Intracellular complement FH promotes renal cancer by modulation of the cell cycle and energy metabolism in fibroblasts and tumour cells
|
| Jayaraman Archana |
Concomitant deficiency of C5aR1 and C5aR2 drives neutrophil dysregulation resulting in increased susceptibility to pneumococcal infection
|
| Joakimsen Ingrid |
Combined complement C3 and CD14 inhibition efficiently reduce the E. coli-induced thromboinflammation in human whole blood in the absence and presence of antibiotics
|
| Jongerius Ilse |
Anti-FHR-1 antibodies reacting against domain 18 of complement factor H have opposing effects on its function; implications for therapeutic enhancement of FH
|
| Jonsson Anna |
Granzyme K activates a new complement pathway
|
| Józsi Mihály |
The complex complement modulatory role of the human factor H-related proteins
|
| Jørgensen Martin |
Cryo-EM analysis of complement C3 reveals a reversible major opening of the macroglobulin ring
|
| Karlsen Baard |
Combined complement C3 and CD14 inhibition efficiently reduce the E. coli-induced thromboinflammation in human whole blood in the absence and presence of antibiotics
|
| Karmash Oleksandr |
Further insights into iptacopan mode of action in IgA nephropathy through protein profiling
|
| Kavian-Tessler Niloufar |
Roles of PTX3 in clearance of SARS-CoV-2 via macrophage phagocytosis of infected epithelial cells
|
| Keefe Dennis |
Nonclinical evaluation of CTx001, a gene therapy for the treatment of geographic atrophy in aged-related macular degeneration
|
| Kemper Claudia |
Complement signaling as an immune checkpoint in the ovarian cancer microenvironment
|
| Khan ANM Nazmul |
Complement signaling as an immune checkpoint in the ovarian cancer microenvironment
|
| Khandelwal Sanjay |
Inhibition of the C1s Protease and the Classical Complement Pathway by
6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide and Chemical Analogs
|
| King Ben |
Protective functions of cytosolic C3 in pancreatic beta cells.
|
| Klint Cecilia |
Elucidating Complement Activation Mechanisms in AAV Gene Therapy: Development of a Novel ELISA-Based Assay for Enhanced Safety and Efficacy
Comprehensive Immunogenicity Analysis of AAV Therapies: Correlating Anti-AAV Antibodies (NAbs/TAbs) with Complement Activation Dynamics
|
| Kolev Martin |
Complement signaling as an immune checkpoint in the ovarian cancer microenvironment
|
| Kollins Dmitrij |
Further insights into iptacopan mode of action in IgA nephropathy through protein profiling
|
| Kotsakis Georgios |
The inflammatory landscape in peri-implantitis and host modulation therapeutic opportunities
|
| Kousik Hrishi |
Obesity and metabolic health shapes mucosal complement responses
|
| Kozma Viktoria |
Elucidating Complement Activation Mechanisms in AAV Gene Therapy: Development of a Novel ELISA-Based Assay for Enhanced Safety and Efficacy
Comprehensive Immunogenicity Analysis of AAV Therapies: Correlating Anti-AAV Antibodies (NAbs/TAbs) with Complement Activation Dynamics
|
| Kronenberg Florian |
Genome-wide association screening of complement activation – data from a general population study
|
| Kuijpers Taco |
Anti-FHR-1 antibodies reacting against domain 18 of complement factor H have opposing effects on its function; implications for therapeutic enhancement of FH
|
| Kulak Klaudia |
Elucidating Complement Activation Mechanisms in AAV Gene Therapy: Development of a Novel ELISA-Based Assay for Enhanced Safety and Efficacy
Comprehensive Immunogenicity Analysis of AAV Therapies: Correlating Anti-AAV Antibodies (NAbs/TAbs) with Complement Activation Dynamics
Protective functions of cytosolic C3 in pancreatic beta cells.
|
| Kulkarni Hrishikesh |
Obesity and metabolic health shapes mucosal complement responses
Complement in chronic allograft dysfunction after lung transplantation
|
| Kuska Katarzyna |
Protective functions of cytosolic C3 in pancreatic beta cells.
|
| Lallemand Christophe |
Comprehensive Immunogenicity Analysis of AAV Therapies: Correlating Anti-AAV Antibodies (NAbs/TAbs) with Complement Activation Dynamics
|
| Lamb Evan |
Complement C5b-C8 and C5b-C9 membrane attack complexes differentially potentiate antimicrobial activity against drug-resistant Neisseria gonorrhoeae
|
| Lambris John |
Combined complement C3 and CD14 inhibition efficiently reduce the E. coli-induced thromboinflammation in human whole blood in the absence and presence of antibiotics
C3 targeting with AMY-101 diminishes IL-8-driven neutrophil chemotaxis in severe COVID-19
Expanding the therapeutic scope of complement C3 inhibition: new paradigms and opportunities
|
| Lamers Christina |
Towards cyclic peptides targeting the complement system
|
| Lau Corinna |
Combined complement C3 and CD14 inhibition efficiently reduce the E. coli-induced thromboinflammation in human whole blood in the absence and presence of antibiotics
|
| Laursen Nick |
BiCE™ – An antibody platform to potentiate complement activation for the treatment of cancer and autoimmune diseases.
|
| Lee Rebecca |
Expanding the therapeutic scope of complement C3 inhibition: new paradigms and opportunities
|
| Li Ping |
Inhibition of the C1s Protease and the Classical Complement Pathway by
6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide and Chemical Analogs
|
| Lin Feng |
Development of C3 humanized rats as preclinical models for evaluating novel human C3-targeted therapeutics
|
| Lionakis Michail |
The Roles of Complement C3 and C5 in Pulmonary Antifungal Immunity
|
| Lysetskiy Mykola |
Further insights into iptacopan mode of action in IgA nephropathy through protein profiling
|
| Magrini Elena |
The role of complement in pancreatic cancer: from complement activation triggering and effector mechanism/s to combination with classical therapies
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Mannes Marco |
Does C2b have a role in inflammation?
Is there a bright side of complement after trauma?
|
| Manoylov Iliyan |
Selective suppression of pathogenic B lymphocytes from Hashimoto's thyroiditis patients by chimeric protein molecules
|
| Mantovani Alberto |
Use of the RNA Technology for the therapy of infectious diseases based on humoral innate immunity molecules
The role of complement in pancreatic cancer: from complement activation triggering and effector mechanism/s to combination with classical therapies
Development of mannose binding lectin as therapeutic agent in COVID-19
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Mapelli Sarah |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Mastellos Dimitrios |
Expanding the therapeutic scope of complement C3 inhibition: new paradigms and opportunities
C3 targeting with AMY-101 diminishes IL-8-driven neutrophil chemotaxis in severe COVID-19
|
| Matola Alexandra |
The complex complement modulatory role of the human factor H-related proteins
|
| Maziarz Karolina |
Protective functions of cytosolic C3 in pancreatic beta cells.
|
| McGray AJ Robert |
Complement signaling as an immune checkpoint in the ovarian cancer microenvironment
|
| McKay Marina |
Protective functions of cytosolic C3 in pancreatic beta cells.
|
| Merchiers Pascal |
BiCE™ – An antibody platform to potentiate complement activation for the treatment of cancer and autoimmune diseases.
|
| Meri Seppo |
Roles of PTX3 in clearance of SARS-CoV-2 via macrophage phagocytosis of infected epithelial cells
|
| Merle Nicolas |
Intracellular C1r promotes kidney cancer progression
Analysing and targeting complement activity in age related macula degeneration of the eye
|
| Mihaylova Nikolina |
Selective suppression of pathogenic B lymphocytes from Hashimoto's thyroiditis patients by chimeric protein molecules
C1q-mimiking scFv fragments binding anti-C1q autoantibodies modulate disease progression in MRL/lpr mouse model of Systemic Lupus Erythematosus
|
| Minery Berenguer Andrea |
Intracellular complement FH promotes renal cancer by modulation of the cell cycle and energy metabolism in fibroblasts and tumour cells
|
| Minute Luna |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Mizgerd Joseph |
Concomitant deficiency of C5aR1 and C5aR2 drives neutrophil dysregulation resulting in increased susceptibility to pneumococcal infection
|
| Mollnes Tom |
Combined complement C3 and CD14 inhibition efficiently reduce the E. coli-induced thromboinflammation in human whole blood in the absence and presence of antibiotics
|
| Monecke Thomas |
The crystal structure of the Factor H-recruiting peptide 5C6 in complex with Factor H domains 8-14 demonstrates an unprecedented domain arrangement in Factor H and allows for rational optimisation of the 5C6 peptide
|
| Monte Alegre Julia |
Dynamic changes in Cytokines and Complement biomarkers during COVID-19: Implications for disease severity and outcomes.
|
| Moreno-Amaral Andrea |
Dynamic changes in Cytokines and Complement biomarkers during COVID-19: Implications for disease severity and outcomes.
|
| Munye Mustafa |
Nonclinical evaluation of CTx001, a gene therapy for the treatment of geographic atrophy in aged-related macular degeneration
|
| Nabizadeh Jamileh |
The Role of Complement Receptor C5aR1 in a Murine Glioblastoma Model
|
| Nair Anup |
Complement pathway inhibition by LHR domain-based duplication variants of Complement Receptor 1.
|
| Natsi Anastasia-Maria |
C3 targeting with AMY-101 diminishes IL-8-driven neutrophil chemotaxis in severe COVID-19
|
| Nester Carla |
Immune complex glomerulonephritis and C3 glomerulopathy in 2024 – state of the art
|
| Niessing Dierk |
The crystal structure of the Factor H-recruiting peptide 5C6 in complex with Factor H domains 8-14 demonstrates an unprecedented domain arrangement in Factor H and allows for rational optimisation of the 5C6 peptide
|
| Nilsson Camilla |
Elucidating Complement Activation Mechanisms in AAV Gene Therapy: Development of a Novel ELISA-Based Assay for Enhanced Safety and Efficacy
Comprehensive Immunogenicity Analysis of AAV Therapies: Correlating Anti-AAV Antibodies (NAbs/TAbs) with Complement Activation Dynamics
|
| Noce Damia |
Genome-wide association screening of complement activation – data from a general population study
|
| Olesen Heidi |
Structure-function analysis of ARGX-117, a calcium- and pH-dependent clinical phase complement C2 blocking antibody
|
| Ozanturk Ayse |
Obesity and metabolic health shapes mucosal complement responses
|
| Pagani Isabel |
Use of the RNA Technology for the therapy of infectious diseases based on humoral innate immunity molecules
Roles of PTX3 in clearance of SARS-CoV-2 via macrophage phagocytosis of infected epithelial cells
Development of mannose binding lectin as therapeutic agent in COVID-19
|
| Panagides Nadya |
The Role of Complement Receptor C5aR1 in a Murine Glioblastoma Model
|
| Pannecoucke Erwin |
Structure-function analysis of ARGX-117, a calcium- and pH-dependent clinical phase complement C2 blocking antibody
|
| Papadimitriou Evangelos |
C3 targeting with AMY-101 diminishes IL-8-driven neutrophil chemotaxis in severe COVID-19
|
| Papp Alexandra |
The complex complement modulatory role of the human factor H-related proteins
|
| Pasqualini Fabio |
Complement activation sustains tumor progression and invasiveness in human and mouse CRC
|
| Patel Nakul |
Nonclinical evaluation of CTx001, a gene therapy for the treatment of geographic atrophy in aged-related macular degeneration
|
| Pattaro Cristian |
Genome-wide association screening of complement activation – data from a general population study
|
| Pedersen Dennis |
BiCE™ – An antibody platform to potentiate complement activation for the treatment of cancer and autoimmune diseases.
|
| Pedotti Mattia |
Development of mannose binding lectin as therapeutic agent in COVID-19
|
| Persson Emma |
Structure-function analysis of ARGX-117, a calcium- and pH-dependent clinical phase complement C2 blocking antibody
The story of empasiprubart (ARGX-117), an inhibitory C2 antibody with sweeping properties, from healthy volunteers to three phase 2 proof-of-concept studies
|
| Pettersen Kristin |
Combined complement C3 and CD14 inhibition efficiently reduce the E. coli-induced thromboinflammation in human whole blood in the absence and presence of antibiotics
|
| Pezone Giovanni |
The role of complement in pancreatic cancer: from complement activation triggering and effector mechanism/s to combination with classical therapies
|
| Pio Ruben |
Complement-related proteins for diagnosis, prognosis and prediction of response in cancer
|
| Pisarenka Sofiya |
Nonclinical evaluation of CTx001, a gene therapy for the treatment of geographic atrophy in aged-related macular degeneration
|
| Plüss Carla |
Towards cyclic peptides targeting the complement system
|
| Polu Krishna |
BiCE™ – An antibody platform to potentiate complement activation for the treatment of cancer and autoimmune diseases.
|
| Poppelaars Felix |
The association of the complotype with on long-term outcome in kidney transplantation
|
| Pouw Richard |
Anti-FHR-1 antibodies reacting against domain 18 of complement factor H have opposing effects on its function; implications for therapeutic enhancement of FH
|
| Powers Glenn |
Complement pathway inhibition by LHR domain-based duplication variants of Complement Receptor 1.
|
| Qamar Ali |
Elucidating Complement Activation Mechanisms in AAV Gene Therapy: Development of a Novel ELISA-Based Assay for Enhanced Safety and Efficacy
|
| Ralchev Nikola |
Selective suppression of pathogenic B lymphocytes from Hashimoto's thyroiditis patients by chimeric protein molecules
C1q-mimiking scFv fragments binding anti-C1q autoantibodies modulate disease progression in MRL/lpr mouse model of Systemic Lupus Erythematosus
|
| RATAJCZAK MARIUSZ |
Expression and activation of intracellular complement (complosome) in human and murine stem cells – novel view on the biology of stem cells.
|
| Rawish Elias |
Targeting the Hypothalamic Complement System: A Novel Approach to Combatting Obesity
|
| Revel Margot |
Intracellular C1r promotes kidney cancer progression
Intracellular complement FH promotes renal cancer by modulation of the cell cycle and energy metabolism in fibroblasts and tumour cells
In situ Complementomics reveals pathological intracellular action of complement C3 in diseases affecting the kidney
|
| Rezola Artero Mikel |
Intracellular C1r promotes kidney cancer progression
Intracellular complement FH promotes renal cancer by modulation of the cell cycle and energy metabolism in fibroblasts and tumour cells
|
| Ricklin Daniel |
The crystal structure of the Factor H-recruiting peptide 5C6 in complex with Factor H domains 8-14 demonstrates an unprecedented domain arrangement in Factor H and allows for rational optimisation of the 5C6 peptide
Decommissioning the initiators: Therapeutic Interference in the early activation steps of the complement response
Towards cyclic peptides targeting the complement system
|
| Risitano Antonio |
C3 targeting with AMY-101 diminishes IL-8-driven neutrophil chemotaxis in severe COVID-19
History of a success: setting proximal complement inhibitors as new treatment paradigm for Paroxysmal Nocturnal Hemoglobinuria
History of a success: setting proximal complement inhibitors as new treatment paradigm for Paroxysmal Nocturnal Hemoglobinuria
|
| Ritis Konstantinos |
C3 targeting with AMY-101 diminishes IL-8-driven neutrophil chemotaxis in severe COVID-19
|
| Rodo Jordi |
Elucidating Complement Activation Mechanisms in AAV Gene Therapy: Development of a Novel ELISA-Based Assay for Enhanced Safety and Efficacy
Comprehensive Immunogenicity Analysis of AAV Therapies: Correlating Anti-AAV Antibodies (NAbs/TAbs) with Complement Activation Dynamics
|
| Rohlik Denise |
Inhibition of the C1s Protease and the Classical Complement Pathway by
6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide and Chemical Analogs
|
| Rolfe Barbara |
The Role of Complement Receptor C5aR1 in a Murine Glioblastoma Model
|
| Rombaut Ans |
The story of empasiprubart (ARGX-117), an inhibitory C2 antibody with sweeping properties, from healthy volunteers to three phase 2 proof-of-concept studies
|
| Roumenina Lubka |
Intracellular C1r promotes kidney cancer progression
In situ Complementomics reveals pathological intracellular action of complement C3 in diseases affecting the kidney
Intracellular complement FH promotes renal cancer by modulation of the cell cycle and energy metabolism in fibroblasts and tumour cells
|
| Rowe Tony |
Complement pathway inhibition by LHR domain-based duplication variants of Complement Receptor 1.
|
| Roy Sourav |
Inhibition of the C1s Protease and the Classical Complement Pathway by
6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide and Chemical Analogs
|
| Rusack Timo |
Targeting the Hypothalamic Complement System: A Novel Approach to Combatting Obesity
|
| Savukoski Susa |
Does C2b have a role in inflammation?
|
| Schmidt Christoph |
Does C2b have a role in inflammation?
The crystal structure of the Factor H-recruiting peptide 5C6 in complex with Factor H domains 8-14 demonstrates an unprecedented domain arrangement in Factor H and allows for rational optimisation of the 5C6 peptide
|
| Schneider Andrea |
The complex complement modulatory role of the human factor H-related proteins
Targeting the Hypothalamic Complement System: A Novel Approach to Combatting Obesity
|
| Schubart Anna |
Further insights into iptacopan mode of action in IgA nephropathy through protein profiling
|
| Schuhmann Imelda |
Further insights into iptacopan mode of action in IgA nephropathy through protein profiling
|
| Schwenkert Michael |
Elucidating Complement Activation Mechanisms in AAV Gene Therapy: Development of a Novel ELISA-Based Assay for Enhanced Safety and Efficacy
Comprehensive Immunogenicity Analysis of AAV Therapies: Correlating Anti-AAV Antibodies (NAbs/TAbs) with Complement Activation Dynamics
|
| Seelen Marc A. |
The association of the complotype with on long-term outcome in kidney transplantation
|
| Segal Brahm H. |
Complement signaling as an immune checkpoint in the ovarian cancer microenvironment
|
| Sen Merve |
Understanding the effects of ARMS2 and its AMD risk variant A69S on extracellular matrix and complement system
Analysing and targeting complement activity in age related macula degeneration of the eye
|
| Sfyroera Georgia |
Expanding the therapeutic scope of complement C3 inhibition: new paradigms and opportunities
|
| Shalai Yaryna |
Further insights into iptacopan mode of action in IgA nephropathy through protein profiling
|
| Sharp Thomas |
selection and characterization of a peptide-based complement activator
Structure determination of complement initiation ‘caught in the act’
|
| Shinkov Alexander |
Selective suppression of pathogenic B lymphocytes from Hashimoto's thyroiditis patients by chimeric protein molecules
|
| Shoibonov Batozhab |
A method to determine the inhibitor potential of the blood to predict uncontrolled activation of the complement system
|
| Shukla Arun |
Molecular insights into activation and signaling of the complement anaphylatoxin receptors
|
| Sichau Jannik |
The crystal structure of the Factor H-recruiting peptide 5C6 in complex with Factor H domains 8-14 demonstrates an unprecedented domain arrangement in Factor H and allows for rational optimisation of the 5C6 peptide
|
| Sironi Marina |
Development of mannose binding lectin as therapeutic agent in COVID-19
|
| Skendros Panagiotis |
C3 targeting with AMY-101 diminishes IL-8-driven neutrophil chemotaxis in severe COVID-19
|
| Slaby Julia |
Protective functions of cytosolic C3 in pancreatic beta cells.
|
| Smith Richard |
Renin in C3 Glomerulopathy by SomaScan
Immune complex glomerulonephritis and C3 glomerulopathy in 2024 – state of the art
|
| Sonderegger Stefan |
The Role of Complement Receptor C5aR1 in a Murine Glioblastoma Model
|
| Sonntag Inga |
Investigating the impact of complement sources and Complement Factor H (CFH) Y402H polymorphism on the stress response of iPSC-RPE cells
|
| Stewart Chelsea |
The Role of Complement Receptor C5aR1 in a Murine Glioblastoma Model
|
| Stravalaci Matteo |
Use of the RNA Technology for the therapy of infectious diseases based on humoral innate immunity molecules
Roles of PTX3 in clearance of SARS-CoV-2 via macrophage phagocytosis of infected epithelial cells
Development of mannose binding lectin as therapeutic agent in COVID-19
|
| Suzuki Sora |
Complement signaling as an immune checkpoint in the ovarian cancer microenvironment
|
| Szakács Dávid |
The complex complement modulatory role of the human factor H-related proteins
|
| Talati Khushi |
Obesity and metabolic health shapes mucosal complement responses
|
| Taylor Amanda |
Immune complex glomerulonephritis and C3 glomerulopathy in 2024 – state of the art
|
| Tchorbanov Andrey |
Selective suppression of pathogenic B lymphocytes from Hashimoto's thyroiditis patients by chimeric protein molecules
C1q-mimiking scFv fragments binding anti-C1q autoantibodies modulate disease progression in MRL/lpr mouse model of Systemic Lupus Erythematosus
|
| Theisen Erin |
Granzyme K activates a new complement pathway
|
| Thurman Joshua M. |
The association of the complotype with on long-term outcome in kidney transplantation
|
| Tozoni Sara |
Dynamic changes in Cytokines and Complement biomarkers during COVID-19: Implications for disease severity and outcomes.
|
| Tsacheva Ivanka |
C1q-mimiking scFv fragments binding anti-C1q autoantibodies modulate disease progression in MRL/lpr mouse model of Systemic Lupus Erythematosus
|
| Tsironidou Victoria |
C3 targeting with AMY-101 diminishes IL-8-driven neutrophil chemotaxis in severe COVID-19
|
| Ueffing Marius |
Understanding the effects of ARMS2 and its AMD risk variant A69S on extracellular matrix and complement system
Analysing and targeting complement activity in age related macula degeneration of the eye
Intracellular complement FH promotes renal cancer by modulation of the cell cycle and energy metabolism in fibroblasts and tumour cells
Investigating the impact of complement sources and Complement Factor H (CFH) Y402H polymorphism on the stress response of iPSC-RPE cells
|
| Umnyakova Ekaterina |
The crystal structure of the Factor H-recruiting peptide 5C6 in complex with Factor H domains 8-14 demonstrates an unprecedented domain arrangement in Factor H and allows for rational optimisation of the 5C6 peptide
|
| Uzonyi Barbara |
The complex complement modulatory role of the human factor H-related proteins
|
| Valentin Marie-Anne |
Further insights into iptacopan mode of action in IgA nephropathy through protein profiling
|
| Vallette Benoit |
Comprehensive Immunogenicity Analysis of AAV Therapies: Correlating Anti-AAV Antibodies (NAbs/TAbs) with Complement Activation Dynamics
|
| van Beek Anna |
Anti-FHR-1 antibodies reacting against domain 18 of complement factor H have opposing effects on its function; implications for therapeutic enhancement of FH
|
| Van de Walle Inge |
Structure-function analysis of ARGX-117, a calcium- and pH-dependent clinical phase complement C2 blocking antibody
The story of empasiprubart (ARGX-117), an inhibitory C2 antibody with sweeping properties, from healthy volunteers to three phase 2 proof-of-concept studies
|
| van Mierlo Gerard |
Anti-FHR-1 antibodies reacting against domain 18 of complement factor H have opposing effects on its function; implications for therapeutic enhancement of FH
|
| Varani Luca |
Development of mannose binding lectin as therapeutic agent in COVID-19
|
| Vicenzi Elisa |
Use of the RNA Technology for the therapy of infectious diseases based on humoral innate immunity molecules
Roles of PTX3 in clearance of SARS-CoV-2 via macrophage phagocytosis of infected epithelial cells
Development of mannose binding lectin as therapeutic agent in COVID-19
|
| Vogt Stephanie |
Towards cyclic peptides targeting the complement system
|
| Von Spitzenbergen Beatriz Akemi |
Dynamic changes in Cytokines and Complement biomarkers during COVID-19: Implications for disease severity and outcomes.
|
| Walachowski Sarah |
Concomitant deficiency of C5aR1 and C5aR2 drives neutrophil dysregulation resulting in increased susceptibility to pneumococcal infection
|
| Walker John |
Inhibition of the C1s Protease and the Classical Complement Pathway by
6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide and Chemical Analogs
|
| Whalley Pamela |
Nonclinical evaluation of CTx001, a gene therapy for the treatment of geographic atrophy in aged-related macular degeneration
|
| Wilkinson Ashley |
Inhibition of the C1s Protease and the Classical Complement Pathway by
6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide and Chemical Analogs
|
| Winkler Mikael |
BiCE™ – An antibody platform to potentiate complement activation for the treatment of cancer and autoimmune diseases.
|
| Wohlgemuth Lisa |
Is there a bright side of complement after trauma?
|
| Woodruff Trent |
Therapeutic inhibition of complement C5aR1 is neuroprotective in Parkinson’s disease preclincal models
|
| Wouters Diana |
Anti-FHR-1 antibodies reacting against domain 18 of complement factor H have opposing effects on its function; implications for therapeutic enhancement of FH
|
| Würzner Reinhard |
Genome-wide association screening of complement activation – data from a general population study
CORVOS (2019-2024) – facilitating more PhD student exchanges and working towards a European Complement PhD
|
| Wymann Sandra |
Complement pathway inhibition by LHR domain-based duplication variants of Complement Receptor 1.
|
| Xu Xin |
Inhibition of the C1s Protease and the Classical Complement Pathway by
6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide and Chemical Analogs
|
| Yancopoulou Despina |
C3 targeting with AMY-101 diminishes IL-8-driven neutrophil chemotaxis in severe COVID-19
Expanding the therapeutic scope of complement C3 inhibition: new paradigms and opportunities
|
| Zamiri Parisa |
Nonclinical evaluation of CTx001, a gene therapy for the treatment of geographic atrophy in aged-related macular degeneration
|
| Zarantonello Alessandra |
Intracellular C1r promotes kidney cancer progression
Intracellular complement FH promotes renal cancer by modulation of the cell cycle and energy metabolism in fibroblasts and tumour cells
|
| Zhang Yuzhou |
Renin in C3 Glomerulopathy by SomaScan
Immune complex glomerulonephritis and C3 glomerulopathy in 2024 – state of the art
|
| Zhong Hang |
Roles of PTX3 in clearance of SARS-CoV-2 via macrophage phagocytosis of infected epithelial cells
Development of mannose binding lectin as therapeutic agent in COVID-19
|
| Zhou Hinman |
Inhibition of the C1s Protease and the Classical Complement Pathway by
6-(4-phenylpiperazin-1-yl)pyridine-3-carboximidamide and Chemical Analogs
|
| Zsiros Emese |
Complement signaling as an immune checkpoint in the ovarian cancer microenvironment
|
| Zub Anastasiia |
Further insights into iptacopan mode of action in IgA nephropathy through protein profiling
|
